$EHC
Encompass Health Corp Stock $ehc

$ehc Overview Financials Valuation SEC Filings Company Website

2013 Q4 Form 10-Q Financial Statement

#000078516113000056 Filed on October 29, 2013

Income Statement

Concept	2013 Q4	2013 Q3	2012 Q4
Revenue	$572.1M	$564.0M	$552.9M
YoY Change	3.47%	5.03%	6.72%
Cost Of Revenue	$27.10M	$25.50M	$26.20M
YoY Change	3.44%	7.14%	0.38%
Gross Profit	$541.4M	$530.5M	$519.5M
YoY Change	4.22%	4.8%	6.92%
Gross Profit Margin	94.63%	94.06%	93.96%
Selling, General & Admin	$315.5M	$314.2M	$315.0M
YoY Change	0.16%	2.18%	5.63%
% of Gross Profit	58.27%	59.23%	60.64%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$25.20M	$24.30M	$21.70M
YoY Change	16.13%	14.08%	7.43%
% of Gross Profit	4.65%	4.58%	4.18%
Operating Expenses	$422.4M	$420.7M	$414.7M
YoY Change	1.86%	4.08%	6.31%
Operating Profit	$119.0M	$109.8M	$104.8M
YoY Change	13.55%	7.65%	9.39%
Interest Expense	-$23.50M	-$23.30M	-$21.30M
YoY Change	10.33%	15.35%	7.04%
% of Operating Profit	-19.75%	-21.22%	-20.32%
Other Income/Expense, Net	$1.300M	$600.0K	$1.100M
YoY Change	18.18%	-90.16%	-8.33%
Pretax Income	$94.60M	$108.4M	$81.90M
YoY Change	15.51%	22.49%	-0.97%
Income Tax	$30.50M	$35.20M	$24.50M
% Of Pretax Income	32.24%	32.47%	29.91%
Net Earnings	$48.90M	$58.20M	$47.00M
YoY Change	4.04%	23.57%	-6.0%
Net Earnings / Revenue	8.55%	10.32%	8.5%
Basic Earnings Per Share	-$0.31	$0.60	$0.43
Diluted Earnings Per Share	-$0.31	$0.58	$0.43
COMMON SHARES
Basic Shares Outstanding	87.43M shares	86.20M shares	95.66M shares
Diluted Shares Outstanding		100.4M shares

Balance Sheet

Concept	2013 Q4	2013 Q3	2012 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$64.50M	$65.00M	$132.8M
YoY Change	-51.43%	-60.17%	341.2%
Cash & Equivalents	$64.50M	$65.00M	$132.8M
Short-Term Investments
Other Short-Term Assets	$115.1M	$119.2M	$117.2M
YoY Change	-1.79%	-13.69%	-15.13%
Inventory
Prepaid Expenses
Receivables	$261.8M	$253.4M	$249.3M
Other Receivables	$12.40M	$0.00	$18.00M
Total Short-Term Assets	$580.4M	$575.1M	$636.8M
YoY Change	-8.86%	4.79%	29.54%
LONG-TERM ASSETS
Property, Plant & Equipment	$910.5M	$893.5M	$748.0M
YoY Change	21.72%	20.86%	12.58%
Goodwill	$456.9M	$457.2M	$437.3M
YoY Change	4.48%	4.55%	3.7%
Intangibles	$88.20M	$87.30M	$73.20M
YoY Change	20.49%	18.61%	26.86%
Long-Term Investments	$18.90M		$19.20M
YoY Change	-1.56%		-29.15%
Other Assets	$144.1M	$130.8M	$135.4M
YoY Change	6.43%	0.08%	5.53%
Total Long-Term Assets	$1.954B	$1.981B	$1.787B
YoY Change	9.32%	3.88%	0.44%
TOTAL ASSETS
Total Short-Term Assets	$580.4M	$575.1M	$636.8M
Total Long-Term Assets	$1.954B	$1.981B	$1.787B
Total Assets	$2.534B	$2.557B	$2.424B
YoY Change	4.55%	4.08%	6.74%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$61.90M	$54.20M	$45.30M
YoY Change	36.64%	4.43%	-0.22%
Accrued Expenses	$114.6M	$257.6M	$111.6M
YoY Change	2.69%	-20.96%	3.81%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$12.30M		$13.60M
YoY Change	-9.56%		-171.96%
Total Short-Term Liabilities	$311.6M	$311.8M	$300.9M
YoY Change	3.56%	-17.47%	-3.93%
LONG-TERM LIABILITIES
Long-Term Debt	$1.505B	$1.306B	$1.240B
YoY Change	21.4%	5.14%	0.33%
Other Long-Term Liabilities	$44.00M	$140.4M	$24.00M
YoY Change	83.33%	1.81%	-21.05%
Total Long-Term Liabilities	$44.00M	$140.4M	$24.00M
YoY Change	83.33%	1.81%	-98.1%
TOTAL LIABILITIES
Total Short-Term Liabilities	$311.6M	$311.8M	$300.9M
Total Long-Term Liabilities	$44.00M	$140.4M	$24.00M
Total Liabilities	$1.959B	$1.758B	$1.671B
YoY Change	17.21%	0.02%	-0.65%
SHAREHOLDERS EQUITY
Retained Earnings	-$2.101B	-$2.150B	-$2.425B
YoY Change	-13.35%		-7.09%
Common Stock	$1.000M	$1.000M	$1.000M
YoY Change	0.0%		0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$404.6M	$404.2M	$163.3M
YoY Change	147.76%		9.74%
Treasury Stock Shares	14.65M shares	14640B shares	5.234M shares
Shareholders Equity	$344.6M	$321.1M	$291.0M
YoY Change
Total Liabilities & Shareholders Equity	$2.534B	$2.557B	$2.424B
YoY Change	4.55%	4.08%	6.74%

Cashflow Statement

Concept	2013 Q4	2013 Q3	2012 Q4
OPERATING ACTIVITIES
Net Income	$48.90M	$58.20M	$47.00M
YoY Change	4.04%	23.57%	-6.0%
Depreciation, Depletion And Amortization	$25.20M	$24.30M	$21.70M
YoY Change	16.13%	14.08%	7.43%
Cash From Operating Activities	$100.9M	$142.6M	$109.3M
YoY Change	-7.69%	33.02%	-15.53%
INVESTING ACTIVITIES
Capital Expenditures	-$34.10M	-$101.5M	-$31.50M
YoY Change	8.25%	200.3%	-33.26%
Acquisitions		$0.00
YoY Change		-100.0%
Other Investing Activities	$5.100M	$5.700M	-$23.00M
YoY Change	-122.17%	-359.09%	127.72%
Cash From Investing Activities	-$29.00M	-$95.80M	-$54.50M
YoY Change	-46.79%	166.11%	-4.89%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-72.40M	-50.50M	-85.20M
YoY Change	-15.02%	-199.21%	-5.02%
NET CHANGE
Cash From Operating Activities	100.9M	142.6M	109.3M
Cash From Investing Activities	-29.00M	-95.80M	-54.50M
Cash From Financing Activities	-72.40M	-50.50M	-85.20M
Net Change In Cash	-500.0K	-3.700M	-30.40M
YoY Change	-98.36%	-103.03%	72.73%
FREE CASH FLOW
Cash From Operating Activities	$100.9M	$142.6M	$109.3M
Capital Expenditures	-$34.10M	-$101.5M	-$31.50M
Free Cash Flow	$135.0M	$244.1M	$140.8M
YoY Change	-4.12%	73.12%	-20.27%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	us-gaap	Cash Provided By Used In Investing Activities Discontinued Operations CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations	0	USD
	us-gaap	Cash Provided By Used In Investing Activities Discontinued Operations CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations	7700000	USD
CY2012Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	45300000	USD
CY2013Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	54200000	USD
CY2013Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	253400000	USD
CY2012Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	249300000	USD
CY2013Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-200000	USD
CY2012Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	1400000	USD
CY2013Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	2874500000	USD
CY2012Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	2876600000	USD
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	18100000	USD
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	19000000	USD
	us-gaap	Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities	51000000	USD
	us-gaap	Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities	128200000	USD
CY2012Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	28700000	USD
CY2013Q3	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	34400000	USD
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	100000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1800000	shares
CY2012Q4	us-gaap	Assets Assets	2424200000	USD
CY2013Q3	us-gaap	Assets Assets	2556500000	USD
CY2013Q3	us-gaap	Assets Current AssetsCurrent	575100000	USD
CY2012Q4	us-gaap	Assets Current AssetsCurrent	636800000	USD
CY2012Q3	us-gaap	Business Acquisitions Pro Forma Net Income Loss BusinessAcquisitionsProFormaNetIncomeLoss	47200000	USD
CY2013Q3	us-gaap	Business Acquisitions Pro Forma Net Income Loss BusinessAcquisitionsProFormaNetIncomeLoss	58200000	USD
	us-gaap	Business Acquisitions Pro Forma Net Income Loss BusinessAcquisitionsProFormaNetIncomeLoss	274300000	USD
	us-gaap	Business Acquisitions Pro Forma Net Income Loss BusinessAcquisitionsProFormaNetIncomeLoss	138100000	USD
CY2013Q3	us-gaap	Business Acquisitions Pro Forma Revenue BusinessAcquisitionsProFormaRevenue	564000000	USD
	us-gaap	Business Acquisitions Pro Forma Revenue BusinessAcquisitionsProFormaRevenue	1706000000	USD
CY2012Q3	us-gaap	Business Acquisitions Pro Forma Revenue BusinessAcquisitionsProFormaRevenue	542400000	USD
	us-gaap	Business Acquisitions Pro Forma Revenue BusinessAcquisitionsProFormaRevenue	1626000000	USD
	us-gaap	Business Combination Pro Forma Information Earnings Or Loss Of Acquiree Since Acquisition Date Actual BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual	-900000	USD
	us-gaap	Business Combination Pro Forma Information Revenue Of Acquiree Since Acquisition Date Actual BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual	6800000	USD
CY2013Q2	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Assets BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets	29300000	USD
CY2013Q2	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities	400000	USD
CY2013Q2	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Net BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet	28900000	USD
CY2013Q2	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Property Plant And Equipment BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment	11300000	USD
CY2013Q3	us-gaap	Capital Lease Obligations CapitalLeaseObligations	90400000	USD
CY2012Q4	us-gaap	Capital Lease Obligations CapitalLeaseObligations	71900000	USD
	us-gaap	Capitalized Computer Software Additions CapitalizedComputerSoftwareAdditions	-15600000	USD
	us-gaap	Capitalized Computer Software Additions CapitalizedComputerSoftwareAdditions	-15700000	USD
CY2012Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	132800000	USD
CY2013Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	65000000	USD
CY2011Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	30100000	USD
CY2012Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	163200000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	133100000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-67800000	USD
CY2013Q3	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	14100000	USD
CY2012Q3	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	12800000	USD
	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	42500000	USD
	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	38600000	USD
CY2013Q3	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	72400000	USD
	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	315600000	USD
	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	178700000	USD
	us-gaap	Cash Provided By Used In Operating Activities Discontinued Operations CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations	-1400000	USD
	us-gaap	Cash Provided By Used In Operating Activities Discontinued Operations CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations	1500000	USD
CY2013Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2012Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	0.18
CY2012Q3	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	0.00
CY2013Q3	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	0.18
	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	0.00
CY2012Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	10000
CY2013Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	10000
CY2013Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000000000	shares
CY2012Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000000000	shares
CY2013Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	102071671000000	shares
CY2012Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	100919297000000	shares
CY2013Q3	us-gaap	Common Stock Value CommonStockValue	1000000	USD
CY2012Q4	us-gaap	Common Stock Value CommonStockValue	1000000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	273100000	USD
CY2013Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	58300000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	140100000	USD
CY2012Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	48200000	USD
CY2012Q3	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	61000000	USD
CY2012Q3	us-gaap	Costs And Expenses CostsAndExpenses	426100000	USD
	us-gaap	Costs And Expenses CostsAndExpenses	1277100000	USD
	us-gaap	Costs And Expenses CostsAndExpenses	1315600000	USD
CY2013Q3	us-gaap	Costs And Expenses CostsAndExpenses	424900000	USD
CY2012Q4	us-gaap	Debt And Capital Lease Obligations DebtAndCapitalLeaseObligations	1253500000	USD
CY2013Q3	us-gaap	Debt And Capital Lease Obligations DebtAndCapitalLeaseObligations	1319900000	USD
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-20800000	USD
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	80400000	USD
CY2012Q4	us-gaap	Deferred Tax Assets Liabilities Net Current DeferredTaxAssetsLiabilitiesNetCurrent	137500000	USD
CY2013Q3	us-gaap	Deferred Tax Assets Liabilities Net Current DeferredTaxAssetsLiabilitiesNetCurrent	137500000	USD
CY2013Q3	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	550100000	USD
CY2013Q3	us-gaap	Deferred Tax Assets Net Current DeferredTaxAssetsNetCurrent	137500000	USD
CY2012Q4	us-gaap	Deferred Tax Assets Net Current DeferredTaxAssetsNetCurrent	137500000	USD
CY2013Q3	us-gaap	Deferred Tax Assets Net Noncurrent DeferredTaxAssetsNetNoncurrent	412600000	USD
CY2012Q4	us-gaap	Deferred Tax Assets Net Noncurrent DeferredTaxAssetsNetNoncurrent	393500000	USD
CY2013Q3	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	35600000	USD
CY2013Q3	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	24300000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	60800000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	69500000	USD
CY2012Q3	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	21300000	USD
	us-gaap	Dividends Common Stock Cash DividendsCommonStockCash	-15900000	USD
	us-gaap	Dividends Preferred Stock DividendsPreferredStock	17200000	USD
	us-gaap	Dividends Preferred Stock DividendsPreferredStock	18100000	USD
CY2013Q3	us-gaap	Dividends Preferred Stock DividendsPreferredStock	5700000	USD
CY2012Q3	us-gaap	Dividends Preferred Stock DividendsPreferredStock	5700000	USD
	us-gaap	Dividends Preferred Stock Cash DividendsPreferredStockCash	18100000	USD
	us-gaap	Dividends Preferred Stock Cash DividendsPreferredStockCash	17200000	USD
CY2012Q4	us-gaap	Due From Related Parties Noncurrent DueFromRelatedPartiesNoncurrent	0	USD
CY2013Q3	us-gaap	Due From Related Parties Noncurrent DueFromRelatedPartiesNoncurrent	0	USD
CY2012Q4	us-gaap	Due To Related Parties Noncurrent DueToRelatedPartiesNoncurrent	0	USD
CY2013Q3	us-gaap	Due To Related Parties Noncurrent DueToRelatedPartiesNoncurrent	0	USD
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	2.86
CY2012Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.43
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.24
CY2013Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.60
CY2011Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.53
CY2011Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.45
CY2011Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.16
CY2011	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.91
CY2011Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.77
CY2008	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	2.70
CY2009	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.77
CY2010	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	9.30
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	2.24
CY2013Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.48
CY2013Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.82
CY2012Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.42
CY2012Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.43
CY2012Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.39
CY2012	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.67
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.24
CY2013Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.58
CY2012Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.43
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	2.68
	us-gaap	Equity Method Investment Dividends Or Distributions EquityMethodInvestmentDividendsOrDistributions	9600000	USD
	us-gaap	Equity Method Investment Dividends Or Distributions EquityMethodInvestmentDividendsOrDistributions	7900000	USD
	us-gaap	Noncash Or Part Noncash Acquisition Other Liabilities Assumed1 NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1	0	USD
CY2012Q3	us-gaap	Equity Method Investment Realized Gain Loss On Disposal EquityMethodInvestmentRealizedGainLossOnDisposal	4900000	USD
	us-gaap	Equity Method Investment Realized Gain Loss On Disposal EquityMethodInvestmentRealizedGainLossOnDisposal	4900000	USD
	us-gaap	Proceeds From Repayments Of Related Party Debt ProceedsFromRepaymentsOfRelatedPartyDebt	0	USD
CY2013Q3	us-gaap	Equity Method Investment Summarized Financial Information Income Loss From Continuing Operations Before Extraordinary Items EquityMethodInvestmentSummarizedFinancialInformationIncomeLossFromContinuingOperationsBeforeExtraordinaryItems	4400000	USD
	us-gaap	Equity Method Investment Summarized Financial Information Income Loss From Continuing Operations Before Extraordinary Items EquityMethodInvestmentSummarizedFinancialInformationIncomeLossFromContinuingOperationsBeforeExtraordinaryItems	21500000	USD
CY2012Q3	us-gaap	Equity Method Investment Summarized Financial Information Income Loss From Continuing Operations Before Extraordinary Items EquityMethodInvestmentSummarizedFinancialInformationIncomeLossFromContinuingOperationsBeforeExtraordinaryItems	7100000	USD
	us-gaap	Equity Method Investment Summarized Financial Information Income Loss From Continuing Operations Before Extraordinary Items EquityMethodInvestmentSummarizedFinancialInformationIncomeLossFromContinuingOperationsBeforeExtraordinaryItems	18400000	USD
CY2012Q3	us-gaap	Equity Method Investment Summarized Financial Information Net Income Loss EquityMethodInvestmentSummarizedFinancialInformationNetIncomeLoss	7100000	USD
	us-gaap	Equity Method Investment Summarized Financial Information Net Income Loss EquityMethodInvestmentSummarizedFinancialInformationNetIncomeLoss	18400000	USD
CY2013Q3	us-gaap	Equity Method Investment Summarized Financial Information Net Income Loss EquityMethodInvestmentSummarizedFinancialInformationNetIncomeLoss	4400000	USD
	us-gaap	Equity Method Investment Summarized Financial Information Net Income Loss EquityMethodInvestmentSummarizedFinancialInformationNetIncomeLoss	21500000	USD
	us-gaap	Equity Method Investment Summarized Financial Information Revenue EquityMethodInvestmentSummarizedFinancialInformationRevenue	55400000	USD
	us-gaap	Equity Method Investment Summarized Financial Information Revenue EquityMethodInvestmentSummarizedFinancialInformationRevenue	64200000	USD
CY2012Q3	us-gaap	Equity Method Investment Summarized Financial Information Revenue EquityMethodInvestmentSummarizedFinancialInformationRevenue	18600000	USD
CY2013Q3	us-gaap	Equity Method Investment Summarized Financial Information Revenue EquityMethodInvestmentSummarizedFinancialInformationRevenue	16200000	USD
CY2012Q3	us-gaap	Fair Value Of Assets Acquired FairValueOfAssetsAcquired	0	USD
CY2013Q3	us-gaap	Fair Value Of Assets Acquired FairValueOfAssetsAcquired	0	USD
	us-gaap	Fair Value Of Assets Acquired FairValueOfAssetsAcquired	-2100000	USD
	us-gaap	Fair Value Of Assets Acquired FairValueOfAssetsAcquired	-15600000	USD
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-1300000	USD
CY2013Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
CY2012Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-1300000	USD
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
CY2013Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	28800000	USD
CY2012Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	29300000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	87300000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	88500000	USD
CY2013Q3	us-gaap	Goodwill Goodwill	457200000	USD
CY2012Q4	us-gaap	Goodwill Goodwill	437300000	USD
CY2013Q2	us-gaap	Goodwill Goodwill	13700000	USD
	us-gaap	Goodwill Acquired During Period GoodwillAcquiredDuringPeriod	-13700000	USD
	us-gaap	Goodwill Acquired During Period GoodwillAcquiredDuringPeriod	0	USD
CY2012Q3	us-gaap	Goodwill Acquired During Period GoodwillAcquiredDuringPeriod	0	USD
CY2013Q3	us-gaap	Goodwill Acquired During Period GoodwillAcquiredDuringPeriod	0	USD
	us-gaap	Health Care Organization Revenue HealthCareOrganizationRevenue	1701100000	USD
CY2012Q3	us-gaap	Health Care Organization Revenue HealthCareOrganizationRevenue	537000000	USD
CY2013Q3	us-gaap	Health Care Organization Revenue HealthCareOrganizationRevenue	564000000	USD
	us-gaap	Health Care Organization Revenue HealthCareOrganizationRevenue	1609000000	USD
CY2013Q3	us-gaap	Impairment Of Long Lived Assets To Be Disposed Of ImpairmentOfLongLivedAssetsToBeDisposedOf	1100000	USD
	us-gaap	Impairment Of Long Lived Assets To Be Disposed Of ImpairmentOfLongLivedAssetsToBeDisposedOf	1100000	USD
	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	275900000	USD
CY2012Q3	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	47600000	USD
CY2013Q3	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	59100000	USD
	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	135400000	USD
	us-gaap	Income Loss From Continuing Operations Attributable To Noncontrolling Entity IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity	38600000	USD
CY2013Q3	us-gaap	Income Loss From Continuing Operations Attributable To Noncontrolling Entity IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity	14100000	USD
	us-gaap	Income Loss From Continuing Operations Attributable To Noncontrolling Entity IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity	42500000	USD
CY2012Q3	us-gaap	Income Loss From Continuing Operations Attributable To Noncontrolling Entity IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity	12800000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	300600000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	258100000	USD
CY2012Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	88500000	USD
CY2013Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	108400000	USD
CY2013Q3	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	73200000	USD
	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	174000000	USD
	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	318400000	USD
CY2012Q3	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	60400000	USD
	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	1.21
	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	2.87
CY2013Q3	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	0.61
CY2012Q3	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	0.44
CY2011Q3	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	0.17
CY2011Q4	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	0.50
CY2011	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	1.39
CY2011Q1	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	0.58
CY2011Q2	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	0.14
CY2010	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	9.20
CY2008	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	2.31
CY2009	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	0.57
CY2013Q1	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	0.48
CY2013Q2	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	1.82
	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	2.24
CY2012	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	1.62
CY2012Q1	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	0.39
CY2012Q4	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	0.41
CY2012Q2	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	0.38
	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	1.21
CY2013Q3	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	0.59
CY2012Q3	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	0.44
	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	2.69
CY2013Q3	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-900000	USD
	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	2600000	USD
	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-1200000	USD
CY2012Q3	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-500000	USD
CY2013Q3	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	-900000	USD
CY2012Q3	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	-500000	USD
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	2600000	USD
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	-1200000	USD
CY2012Q3	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	-0.01
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	0.03
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	-0.01
CY2013Q3	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	-0.01
CY2011Q4	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	-0.05
CY2011Q2	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	0.02
CY2011Q1	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	0.19
	us-gaap	Management Fees Revenue ManagementFeesRevenue	0	USD
CY2011Q3	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	0.36
CY2011	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	0.52
CY2008	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	0.39
CY2009	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	0.20
CY2010	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	0.10
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	0.00
CY2013Q1	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	0.00
CY2013Q2	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	0.00
CY2012	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	0.05
CY2012Q4	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	0.02
CY2012Q1	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	0.00
CY2012Q2	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	0.04
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	0.03
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	-0.01
CY2013Q3	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	-0.01
CY2012Q3	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	-0.01
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	8200000	USD
CY2012Q3	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	3300000	USD
CY2013Q3	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	2000000	USD
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	9700000	USD
CY2013Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	35200000	USD
CY2012Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	28100000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-17800000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	84100000	USD
CY2012Q3	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	1000000	USD
	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	4000000	USD
	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	1000000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1400000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	9900000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	42300000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	26500000	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	8000000	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	4500000	USD
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-6600000	USD
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-2500000	USD
	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	-7600000	USD
	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	3900000	USD
	us-gaap	Incremental Common Shares Attributable To Conversion Of Preferred Stock IncrementalCommonSharesAttributableToConversionOfPreferredStock	11600000	shares
CY2013Q3	us-gaap	Incremental Common Shares Attributable To Conversion Of Preferred Stock IncrementalCommonSharesAttributableToConversionOfPreferredStock	11600000	shares
	us-gaap	Incremental Common Shares Attributable To Conversion Of Preferred Stock IncrementalCommonSharesAttributableToConversionOfPreferredStock	12200000	shares
CY2012Q3	us-gaap	Incremental Common Shares Attributable To Conversion Of Preferred Stock IncrementalCommonSharesAttributableToConversionOfPreferredStock	11600000	shares
	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	2100000	shares
CY2013Q3	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	2600000	shares
	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	1400000	shares
CY2012Q3	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	1800000	shares
CY2012Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	73200000	USD
	us-gaap	Noncash Or Part Noncash Acquisition Intangible Assets Acquired1 NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1	0	USD
CY2012Q4	us-gaap	Long Term Debt And Capital Lease Obligations LongTermDebtAndCapitalLeaseObligations	1239900000	USD
CY2013Q3	us-gaap	Long Term Debt And Capital Lease Obligations LongTermDebtAndCapitalLeaseObligations	1306200000	USD
CY2013Q3	us-gaap	Long Term Debt And Capital Lease Obligations Current LongTermDebtAndCapitalLeaseObligationsCurrent	13700000	USD
CY2012Q4	us-gaap	Long Term Debt And Capital Lease Obligations Current LongTermDebtAndCapitalLeaseObligationsCurrent	13600000	USD
	us-gaap	Loss Contingency Disclosures LossContingencyDisclosures	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Contingencies and Other Commitments </font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We operate in a highly regulated and litigious industry. As a result, various lawsuits, claims, and legal and regulatory proceedings have been and can be expected to be instituted or asserted against us. The resolution of any such lawsuits, claims, or legal and regulatory proceedings could materially and adversely affect our financial position, results of operations, and cash flows in a given period. </font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Litigation By and Against Former Independent Auditor—</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In March 2003, claims on behalf of HealthSouth were brought against Ernst & Young, LLP in a stockholder derivative lawsuit initially filed in the Circuit Court of Jefferson County, Alabama on August 28, 2002 and captioned </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Tucker v. Scrushy</font><font style="font-family:inherit;font-size:10pt;">. The </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Tucker</font><font style="font-family:inherit;font-size:10pt;"> derivative litigation, including the claims against various other defendants and the </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$2.9 billion</font><font style="font-family:inherit;font-size:10pt;"> judgment against Mr. Scrushy, our former chairman and chief executive officer, is more fully described in “Derivative Litigation” and “Litigation Against Richard M. Scrushy” in Note 19, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Contingencies and Other Commitments</font><font style="font-family:inherit;font-size:10pt;">, to the consolidated financial statements accompanying the 2012 Form 10-K. The </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Tucker</font><font style="font-family:inherit;font-size:10pt;"> complaint alleges that from 1996 through 2002, when Ernst & Young served as our independent auditor, Ernst & Young acted recklessly and with gross negligence in performing its duties, and specifically that Ernst & Young failed to perform reviews and audits of our financial statements with due professional care as required by law and by its contractual agreements with us. The claims further allege Ernst & Young either knew of or, in the exercise of due care, should have discovered and investigated the fraudulent and improper accounting practices being directed by certain officers and employees, and should have reported them to our board of directors and the audit committee. The claims seek compensatory and punitive damages, disgorgement of fees received from us by Ernst & Young, and attorneys’ fees and costs. </font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On March 18, 2005, Ernst & Young filed a lawsuit captioned </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Ernst & Young LLP v. HealthSouth Corp.</font><font style="font-family:inherit;font-size:10pt;"> in the Circuit Court of Jefferson County, Alabama. The complaint alleges we provided Ernst & Young with fraudulent management representation letters, financial statements, invoices, bank reconciliations, and journal entries in an effort to conceal accounting fraud. Ernst & Young claims that as a result of our actions, Ernst & Young’s reputation has been injured and it has and will incur damages, expenses, and legal fees. On April 1, 2005, we answered Ernst & Young’s claims and asserted counterclaims related or identical to those asserted in the </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Tucker</font><font style="font-family:inherit;font-size:10pt;"> action. Upon Ernst & Young’s motion, the Alabama state court referred Ernst & Young’s claims and our counterclaims to arbitration pursuant to a clause in the engagement agreements between HealthSouth and Ernst & Young. In August 2006, we and the derivative plaintiffs agreed to jointly prosecute the claims against Ernst & Young in arbitration. </font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The trial phase of the arbitration process began on July 12, 2010 before a three-person arbitration panel selected under rules of the American Arbitration Association (the “AAA”). On December 18, 2012, the AAA panel granted Ernst & Young’s motion to dismiss our claims on the grounds that HealthSouth is not permitted to pursue its claims since certain of its former officers and employees committed fraudulent acts. The panel also denied and dismissed Ernst & Young’s claims against us. On December 18, 2012, we, together with the stockholder derivative plaintiffs, filed a notice of appeal of the panel’s decision in the Circuit Court of Jefferson County, Alabama. On December 28, 2012, we filed a motion to vacate the decision. We assert that the panel’s decision is contrary to the Federal Arbitration Act and the duties of a public accounting firm to its corporate clients, and that the arbitrators exceeded their authority by entering an award contrary to Alabama law. On April 25, 2013, the court denied our motion to vacate. On June 4, 2013, we filed a notice of appeal to the Supreme Court of Alabama seeking review of the Circuit Court's denial of our motion to vacate the arbitration panel's decision, and the briefing schedule has begun.</font><font style="font-family:inherit;font-size:10pt;color:#0000ff;"> </font><font style="font-family:inherit;font-size:10pt;">At this time, we do not know how long the appellate process will take. </font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Based on the ruling of the arbitration panel, we do not believe there is a reasonable possibility of a loss that might result from an adverse judgment or a settlement of this case.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">General Medicine Action—</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On August 16, 2004, General Medicine, P.C. filed a lawsuit against us captioned </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">General Medicine, P.C. v. HealthSouth Corp.</font><font style="font-family:inherit;font-size:10pt;"> seeking the recovery of allegedly fraudulent transfers involving assets of Horizon/CMS Healthcare Corporation, a former subsidiary of HealthSouth. The lawsuit is pending in the Circuit Court of Jefferson County, Alabama (the “Alabama Action”).</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:13px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">General Medicine’s underlying claim against Horizon/CMS originates from a services contract entered into in 1995 between General Medicine and Horizon/CMS whereby General Medicine agreed to provide medical director services to skilled nursing facilities owned by Horizon/CMS for a term of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">three years</font><font style="font-family:inherit;font-size:10pt;">. Horizon/CMS terminated the agreement for cause six months after it was executed, and General Medicine then initiated a lawsuit against Horizon/CMS in the United States District Court for the Eastern District of Michigan in 1996 (the “Michigan Action”). General Medicine’s complaint in the Michigan Action alleged that Horizon/CMS breached the services contract by wrongfully terminating General Medicine. We acquired Horizon/CMS in 1997 and sold it to Meadowbrook Healthcare, Inc. in 2001 pursuant to a stock purchase agreement. In 2004, Meadowbrook, without the knowledge of HealthSouth, consented to the entry of a final judgment in the Michigan Action in favor of General Medicine against Horizon/CMS for the alleged wrongful termination of the contract with General Medicine in the amount of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$376 million</font><font style="font-family:inherit;font-size:10pt;">, plus interest from the date of the judgment until paid at the rate of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">10%</font><font style="font-family:inherit;font-size:10pt;"> per annum (the “Consent Judgment”). The </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$376 million</font><font style="font-family:inherit;font-size:10pt;"> damages figure was unilaterally selected by General Medicine and was not tested or opposed by Meadowbrook. Additionally, the settlement agreement (the “Settlement”) used as the basis for the Consent Judgment provided that Meadowbrook would pay only </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$300,000</font><font style="font-family:inherit;font-size:10pt;"> to General Medicine to settle the Michigan Action and that General Medicine would seek to recover the remaining balance of the Consent Judgment solely from us. We were not a party to the Michigan Action, the Settlement negotiated by Meadowbrook, or the Consent Judgment. </font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The complaint filed by General Medicine against us in the Alabama Action alleges that while Horizon/CMS was our wholly owned subsidiary, General Medicine was an existing creditor of Horizon/CMS by virtue of the breach of contract claim underlying the Settlement. The complaint also alleges we caused Horizon/CMS to transfer its assets to us for less than a reasonably equivalent value or, in the alternative, with the actual intent to defraud creditors of Horizon/CMS, including General Medicine, in violation of the Alabama Uniform Fraudulent Transfer Act. General Medicine further alleges in its amended complaint that we are liable for the Consent Judgment despite not being a party to it because as Horizon/CMS’s parent we failed to observe corporate formalities in our operation and ownership of Horizon/CMS, misused our control of Horizon/CMS, stripped assets from Horizon/CMS, and engaged in other conduct which amounted to a fraud on Horizon/CMS’s creditors. General Medicine has requested relief including recovery of the unpaid amount of the Consent Judgment, the avoidance of the subject transfers of assets, attachment of the assets transferred to us, appointment of a receiver over the transferred properties, and a monetary judgment for the value of properties transferred. </font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have denied liability to General Medicine and asserted counterclaims against General Medicine for fraud, injurious falsehood, tortious interference with business relations, conspiracy, unjust enrichment, abuse of process, and other causes of action. In our counterclaims, we alleged the Consent Judgment is the product of fraud, collusion and bad faith by General Medicine and Meadowbrook and, further, that these parties were guilty of a conspiracy to manufacture a lawsuit against HealthSouth in favor of General Medicine. Consequently, we assert that the Consent Judgment is not evidence of a legitimate debt owed by Horizon/CMS to General Medicine that is collectible from HealthSouth under any theory of liability.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In 2008, after we obtained discovery concerning the circumstances that led to the entry of the Consent Judgment, we filed a motion in the Michigan Action asking the court to set aside the Consent Judgment on grounds that it was the product of fraud on the court and collusion by the parties. On May 21, 2009, the court granted our motion to set aside the Consent Judgment on grounds that it was the product of fraud on the court. On March 9, 2010, General Medicine filed an appeal of the court's decision to the Sixth Circuit Court of Appeals. The parties agreed to a voluntary stay of the Alabama Action pending the outcome of General Medicine's appeal to the Sixth Circuit Court of Appeals. On April 10, 2012, the Sixth Circuit Court of Appeals reversed the lower court's ruling and reinstated the Consent Judgment. Due to the conclusion of the appeal in the Michigan Action, General Medicine requested reactivation of the Alabama Action in the Circuit Court of Jefferson County, Alabama. On January 10, 2013, we filed a motion for partial summary judgment in the Alabama Action seeking a declaration that the Consent Judgment obtained by General Medicine is not enforceable against us because, among other reasons, it was the result of collusion. On February 27, 2013, the court denied our motion and reserved the issue of collusion for a later time. The court issued a supplemental order on April 11, 2013, clarifying its February 27, 2013 ruling. The court's rulings provide that the Consent Judgment is admissible as evidence of General Medicine's claim in the Alabama Action but the amount of the Consent Judgment is not binding on us. Therefore, we remain free to present evidence challenging the amount of the damages figure contained in the Consent Judgment, including the value of the underlying contract-related claim that is the basis for the Consent Judgment. The court further ruled that we may develop and present evidence that the Consent Judgment is void in its entirety as the product of collusion by General Medicine and Horizon/CMS. The court also indicated it concurred with the Sixth Circuit Court of Appeals that the Consent Judgment did nothing more than establish Horizon/CMS's liability to General Medicine and did not establish the merits of General Medicine's separate fraudulent conveyance claims against HealthSouth. The Alabama Action is still in the discovery phase and has been set for trial beginning in June 2014.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Based on the stage of litigation, review of the current facts and circumstances as we understand them, the nature of the underlying claim, the results of the proceedings to date, and the nature and scope of the defense we continue to mount, we do not believe an adverse judgment or settlement is probable in this matter, and it is also not possible to estimate the amount of loss, if any, or range of possible loss that might result from an adverse judgment or settlement of this case. We intend to vigorously defend ourselves against General Medicine’s claims and to vigorously prosecute our counterclaims against General Medicine.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Other Litigation—</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have been named as a defendant in a lawsuit filed March 28, 2003 by several individual stockholders in the Circuit Court of Jefferson County, Alabama, captioned </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Nichols v. HealthSouth Corp</font><font style="font-family:inherit;font-size:10pt;">. The plaintiffs allege that we, some of our former officers, and our former investment bank engaged in a scheme to overstate and misrepresent our earnings and financial position. The plaintiffs are seeking compensatory and punitive damages. This case was consolidated with the </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Tucker</font><font style="font-family:inherit;font-size:10pt;"> case for discovery and other pretrial purposes and was stayed in the Circuit Court on August 8, 2005. The plaintiffs filed an amended complaint on November 9, 2010 to which we responded with a motion to dismiss filed on December 22, 2010. During a hearing on February 24, 2012, plaintiffs’ counsel indicated his intent to dismiss certain claims against us. Instead, on March 9, 2012, the plaintiffs amended their complaint to include additional securities fraud claims against HealthSouth and add several former officers to the lawsuit. On September 12, 2012, the plaintiffs further amended their complaint to request certification as a class action. One of those named officers has repeatedly attempted to remove the case to federal district court, most recently on December 11, 2012. We filed our latest motion to remand the case back to state court on January 10, 2013. On September 27, 2013, the federal court remanded the case back to state court. We intend to vigorously defend ourselves in this case. Based on the stage of litigation, review of the current facts and circumstances as we understand them, the nature of the underlying claim, the results of the proceedings to date, and the nature and scope of the defense we continue to mount, we do not believe an adverse judgment or settlement is probable in this matter, and it is also not possible to estimate the amount of loss, if any, or range of possible loss that might result from an adverse judgment or settlement of this case.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We were named as a defendant in a lawsuit filed March 3, 2009 by an individual in the Court of Common Pleas, Richland County, South Carolina, captioned </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Sulton v. HealthSouth Corp, et al.</font><font style="font-family:inherit;font-size:10pt;"> The plaintiff alleged that certain treatment he received at a HealthSouth facility complicated a pre-existing infectious injury. The plaintiff sought recovery for pain and suffering, medical expenses, punitive damages, and other damages. On July 30, 2010, the jury in this case returned a verdict in favor of the plaintiff for </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$12.3 million</font><font style="font-family:inherit;font-size:10pt;"> in damages. We appealed that verdict, and on November 21, 2012, the Supreme Court of South Carolina reversed the jury verdict in its entirety and remanded the case to the court of common pleas for retrial. On March 8, 2013, the Court of Common Pleas, Richland County, South Carolina approved our comprehensive settlement agreement with the plaintiff in the </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Sulton</font><font style="font-family:inherit;font-size:10pt;"> case. While the terms of the settlement are confidential, the amount paid to the plaintiff to settle all claims was not material to us and was less than amounts previously accrued. See Note 10, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Self-Insured Risks,</font><font style="font-family:inherit;font-size:10pt;"> to the consolidated financial statements accompanying the 2012 Form 10-K.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">HHS-OIG Investigations—</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On June 24, 2011, we received a document subpoena addressed to HealthSouth Hospital of Houston, a long-term acute care hospital (“LTCH”) we closed in August 2011, and issued from the Dallas, Texas office of the U.S. Department of Health and Human Services, Office of the Inspector General (the “HHS-OIG”). The subpoena is in connection with an investigation of possible false or otherwise improper claims submitted to Medicare and Medicaid and requests documents and materials relating to this closed LTCH’s patient admissions, length of stay, and discharge matters. </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On March 4, 2013, we received document subpoenas addressed to </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">four</font><font style="font-family:inherit;font-size:10pt;"> of our wholly owned hospitals and issued from the Miami Lakes, Florida office of the HHS-OIG. These hospitals process all of their Medicare claims through the same Medicare administrative contractor, Cahaba Government Benefit Administrators, LLC. Each subpoena is in connection with an investigation of alleged improper or fraudulent claims submitted to Medicare and Medicaid and requests documents and materials relating to practices, procedures, protocols and policies, of certain pre- and post-admissions activities at these hospitals including, among other things, marketing functions, pre-admission screening, post-admission physician evaluations, patient assessment instruments, individualized patient plans of care, and compliance with the Medicare </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">60%</font><font style="font-family:inherit;font-size:10pt;"> rule. Under the Medicare rule commonly referred to as the “</font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">60%</font><font style="font-family:inherit;font-size:10pt;"> rule,” an inpatient rehabilitation hospital must treat </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">60%</font><font style="font-family:inherit;font-size:10pt;"> or more of its patients from at least one of a specified list of medical conditions in order to be reimbursed at the inpatient rehabilitation hospital payment rates, rather than at the lower acute care hospital payment rates. The subpoenas also request complete copies of medical records for </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">100</font><font style="font-family:inherit;font-size:10pt;"> patients treated at each of these hospitals between September 2008 and June 2012.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are cooperating fully with the HHS-OIG in connection with these subpoenas and are currently unable to predict the timing or outcome of the related investigations. </font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Other Matters—</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The False Claims Act, 18 U.S.C. § 287, allows private citizens, called “relators,” to institute civil proceedings alleging violations of the False Claims Act. These </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">qui tam</font><font style="font-family:inherit;font-size:10pt;"> cases are generally sealed by the court at the time of filing. The only parties privy to the information contained in the complaint are the relator, the federal government, and the presiding court. It is possible that </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">qui tam</font><font style="font-family:inherit;font-size:10pt;"> lawsuits have been filed against us and that we are unaware of such filings or have been ordered by the presiding court not to discuss or disclose the filing of such lawsuits. We may be subject to liability under one or more undisclosed </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">qui tam</font><font style="font-family:inherit;font-size:10pt;"> cases brought pursuant to the False Claims Act.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">It is our obligation as a participant in Medicare and other federal healthcare programs to routinely conduct audits and reviews of the accuracy of our billing systems and other regulatory compliance matters. As a result of these reviews, we have made, and will continue to make, disclosures to the HHS-OIG and the United States Centers for Medicare and Medicaid Services (“CMS”) relating to amounts we suspect represent over-payments from these programs, whether due to inaccurate billing or otherwise. Some of these disclosures have resulted in, or may result in, HealthSouth refunding amounts to Medicare or other federal healthcare programs. </font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In March 2008, we sold our corporate campus to Daniel Corporation (“Daniel”), a Birmingham, Alabama-based real estate company. The sale included a deferred purchase price component related to an incomplete 13-story building located on the property, often referred to as the Digital Hospital. Under the agreement, Daniel was obligated upon sale of its interest in the building to pay to us </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">40%</font><font style="font-family:inherit;font-size:10pt;"> of the net profit realized from the sale. In June 2013, Daniel sold the building to Trinity Medical Center. In the third quarter of 2013, we received </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$10.8 million</font><font style="font-family:inherit;font-size:10pt;"> in cash from Daniel in connection with the sale of the building. The gain associated with this transaction is being deferred and amortized over five years, which is the remaining life of our lease agreement with Daniel for the portion of the property we continue to occupy with our corporate office, as a component of </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">General and administrative expenses</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pursuant to legislative directives and authorizations from Congress, CMS has developed and instituted various Medicare audit programs under which CMS contracts with private companies to conduct claims and medical record audits. One type of audit contractor, the Recovery Audit Contractors, began post-payment audit processes in late 2009 for providers in general. In connection with CMS approved and announced audits related to inpatient rehabilitation facilities, we have recently received requests to review certain patient files for discharges occurring from 2010 to 2013. To date, the Medicare payments that are subject to these audit requests represent less than </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">1%</font><font style="font-family:inherit;font-size:10pt;"> of our average annual patient discharges over the past three years. However, it is too early for us to assess the ultimate scope of the review, the number of claims that might subsequently be denied, and the ultimate result of any appeal or adjudication process. </font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As discussed in Note 19, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Contingencies and Other Commitments</font><font style="font-family:inherit;font-size:10pt;">, “Litigation Against Richard M. Scrushy,” to the consolidated financial statements accompanying the 2012 Form 10-K, we previously recorded an estimated liability for the plaintiffs in the 2004 consolidated securities action for amounts claimed by them under the 2007 comprehensive settlement of that action brought against us by our stockholders and bondholders. Specifically, this estimate related to the plaintiffs’ claim for </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">25%</font><font style="font-family:inherit;font-size:10pt;"> apportionment of any net recovery from Richard Scrushy, Ernst & Young LLP, and UBS. In September 2013, these plaintiffs filed a request with the federal court overseeing the settlement to approve an agreement reached on how to calculate this apportionment obligation. As a result of this filing with the court, we recorded a noncash reduction to the liability originally recorded in 2006 for this obligation during the third quarter of 2013 through the line item </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Government, class action, and related settlements </font><font style="font-family:inherit;font-size:10pt;">in our condensed consolidated statements of operations.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition, we have resolved all claims against former officers other than Richard Scrushy who were remaining as defendants in the derivative lawsuit discussed in Note 19, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Contingencies and Other Commitments</font><font style="font-family:inherit;font-size:10pt;">, “Derivative Litigation,” to the consolidated financial statements accompanying the 2012 Form 10-K. These resolutions included the entry of final judgments against five former officers and resulted in the collection of approximately </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$5 million</font><font style="font-family:inherit;font-size:10pt;"> during the third quarter of 2013. These collections were included in the line item </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Government, class action, and related settlements</font><font style="font-family:inherit;font-size:10pt;"> in our condensed consolidated statements of operations for the three and nine months ended September 30, 2013.</font></div></div>
CY2012Q3	us-gaap	Management Fees Revenue ManagementFeesRevenue	0	USD
CY2013Q3	us-gaap	Management Fees Revenue ManagementFeesRevenue	0	USD
	us-gaap	Management Fees Revenue ManagementFeesRevenue	0	USD
CY2012Q4	us-gaap	Minority Interest MinorityInterest	112500000	USD
CY2013Q3	us-gaap	Minority Interest MinorityInterest	120900000	USD
	us-gaap	Minority Interest Decrease From Distributions To Noncontrolling Interest Holders MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders	34200000	USD
	us-gaap	Minority Interest Decrease From Distributions To Noncontrolling Interest Holders MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders	30100000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-240000000	USD
CY2013Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	87300000	USD
	us-gaap	Interest And Debt Expense InterestAndDebtExpense	73900000	USD
CY2013Q3	us-gaap	Interest And Debt Expense InterestAndDebtExpense	25300000	USD
CY2012Q3	us-gaap	Interest And Debt Expense InterestAndDebtExpense	23500000	USD
	us-gaap	Interest And Debt Expense InterestAndDebtExpense	69800000	USD
CY2013Q3	us-gaap	Investments In Affiliates Subsidiaries Associates And Joint Ventures InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures	19100000	USD
CY2012Q4	us-gaap	Investments In Affiliates Subsidiaries Associates And Joint Ventures InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures	20800000	USD
	us-gaap	Labor And Related Expense LaborAndRelatedExpense	780700000	USD
CY2012Q3	us-gaap	Labor And Related Expense LaborAndRelatedExpense	262300000	USD
	us-gaap	Labor And Related Expense LaborAndRelatedExpense	817700000	USD
CY2013Q3	us-gaap	Labor And Related Expense LaborAndRelatedExpense	269500000	USD
CY2013Q3	us-gaap	Liabilities Liabilities	1758400000	USD
CY2012Q4	us-gaap	Liabilities Liabilities	1671300000	USD
CY2013Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	2556500000	USD
CY2012Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	2424200000	USD
CY2012Q4	us-gaap	Liabilities Current LiabilitiesCurrent	300900000	USD
CY2013Q3	us-gaap	Liabilities Current LiabilitiesCurrent	311800000	USD
CY2012Q4	us-gaap	Line Of Credit LineOfCredit	0	USD
CY2013Q3	us-gaap	Line Of Credit LineOfCredit	35000000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-44800000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-197200000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-124300000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	369400000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	302200000	USD
	us-gaap	Net Income Loss NetIncomeLoss	274700000	USD
	us-gaap	Net Income Loss NetIncomeLoss	138000000	USD
CY2012Q3	us-gaap	Net Income Loss NetIncomeLoss	47100000	USD
CY2013Q3	us-gaap	Net Income Loss NetIncomeLoss	58200000	USD
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	38600000	USD
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	42500000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	274700000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	138000000	USD
CY2012Q3	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	47100000	USD
CY2013Q3	us-gaap	Noncash Or Part Noncash Acquisition Intangible Assets Acquired1 NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1	0	USD
CY2012Q3	us-gaap	Noncash Or Part Noncash Acquisition Intangible Assets Acquired1 NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1	-1000000	USD
	us-gaap	Noncash Or Part Noncash Acquisition Intangible Assets Acquired1 NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1	-1000000	USD
CY2013Q3	us-gaap	Noncash Or Part Noncash Acquisition Other Liabilities Assumed1 NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1	0	USD
CY2013Q3	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	14100000	USD
CY2012Q3	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	12800000	USD
	us-gaap	Net Income Loss Attributable To Nonredeemable Noncontrolling Interest NetIncomeLossAttributableToNonredeemableNoncontrollingInterest	35600000	USD
CY2013Q3	us-gaap	Net Income Loss Attributable To Nonredeemable Noncontrolling Interest NetIncomeLossAttributableToNonredeemableNoncontrollingInterest	12600000	USD
	us-gaap	Net Income Loss Attributable To Nonredeemable Noncontrolling Interest NetIncomeLossAttributableToNonredeemableNoncontrollingInterest	38400000	USD
CY2012Q3	us-gaap	Net Income Loss Attributable To Nonredeemable Noncontrolling Interest NetIncomeLossAttributableToNonredeemableNoncontrollingInterest	11700000	USD
	us-gaap	Net Income Loss Attributable To Redeemable Noncontrolling Interest NetIncomeLossAttributableToRedeemableNoncontrollingInterest	4100000	USD
CY2013Q3	us-gaap	Net Income Loss Attributable To Redeemable Noncontrolling Interest NetIncomeLossAttributableToRedeemableNoncontrollingInterest	1500000	USD
CY2012Q3	us-gaap	Net Income Loss Attributable To Redeemable Noncontrolling Interest NetIncomeLossAttributableToRedeemableNoncontrollingInterest	1100000	USD
	us-gaap	Net Income Loss Attributable To Redeemable Noncontrolling Interest NetIncomeLossAttributableToRedeemableNoncontrollingInterest	3000000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	257500000	USD
CY2013Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	52500000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	119100000	USD
CY2012Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	41400000	USD
CY2013Q3	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	58200000	USD
CY2012Q3	us-gaap	Noncash Or Part Noncash Acquisition Other Liabilities Assumed1 NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1	0	USD
	us-gaap	Noncash Or Part Noncash Acquisition Other Liabilities Assumed1 NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1	-400000	USD
	us-gaap	Noncontrolling Interest Increase From Business Combination NoncontrollingInterestIncreaseFromBusinessCombination	13900000	USD
CY2013Q3	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	1000000000	USD
CY2012Q4	us-gaap	Other Assets Current OtherAssetsCurrent	117200000	USD
CY2013Q3	us-gaap	Other Assets Current OtherAssetsCurrent	119200000	USD
CY2013Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	130800000	USD
CY2012Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	135400000	USD
CY2012Q3	us-gaap	Other Comprehensive Income Loss Before Tax OtherComprehensiveIncomeLossBeforeTax	1100000	USD
	us-gaap	Other Comprehensive Income Loss Before Tax OtherComprehensiveIncomeLossBeforeTax	2100000	USD
CY2013Q3	us-gaap	Other Comprehensive Income Loss Before Tax OtherComprehensiveIncomeLossBeforeTax	100000	USD
	us-gaap	Other Comprehensive Income Loss Before Tax OtherComprehensiveIncomeLossBeforeTax	-1700000	USD
CY2012Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	1100000	USD
CY2013Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	100000	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-1600000	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	2100000	USD
CY2013Q3	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Before Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax	-100000	USD
	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Before Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax	900000	USD
	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Before Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax	0	USD
CY2012Q3	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Before Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax	0	USD
	us-gaap	Other Comprehensive Income Loss Tax OtherComprehensiveIncomeLossTax	0	USD
CY2012Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	1100000	USD
CY2012Q3	us-gaap	Other Comprehensive Income Loss Tax OtherComprehensiveIncomeLossTax	0	USD
CY2013Q3	us-gaap	Other Comprehensive Income Loss Tax OtherComprehensiveIncomeLossTax	0	USD
	us-gaap	Other Comprehensive Income Loss Tax OtherComprehensiveIncomeLossTax	-100000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-800000	USD
	us-gaap	Proceeds From Repayments Of Related Party Debt ProceedsFromRepaymentsOfRelatedPartyDebt	0	USD
CY2013Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	0	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	2100000	USD
	us-gaap	Other Cost And Expense Operating OtherCostAndExpenseOperating	241300000	USD
CY2013Q3	us-gaap	Other Cost And Expense Operating OtherCostAndExpenseOperating	82200000	USD
	us-gaap	Other Cost And Expense Operating OtherCostAndExpenseOperating	225800000	USD
CY2012Q3	us-gaap	Other Cost And Expense Operating OtherCostAndExpenseOperating	77000000	USD
CY2012Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	255600000	USD
CY2013Q3	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	257600000	USD
CY2012Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	130500000	USD
CY2013Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	140400000	USD
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-1700000	USD
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-6000000	USD
CY2012Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	6100000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	7400000	USD
CY2013Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	600000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	3200000	USD
CY2013Q3	us-gaap	Other Notes Payable OtherNotesPayable	49700000	USD
CY2012Q4	us-gaap	Other Notes Payable OtherNotesPayable	36800000	USD
	us-gaap	Partners Capital Account Contributions PartnersCapitalAccountContributions	11400000	USD
	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	0	USD
	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	1600000	USD
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	234100000	USD
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	0	USD
	us-gaap	Payments For Repurchase Of Convertible Preferred Stock PaymentsForRepurchaseOfConvertiblePreferredStock	46000000	USD
	us-gaap	Payments For Repurchase Of Convertible Preferred Stock PaymentsForRepurchaseOfConvertiblePreferredStock	0	USD
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	7000000	USD
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	1200000	USD
	us-gaap	Payments Of Dividends Minority Interest PaymentsOfDividendsMinorityInterest	34100000	USD
	us-gaap	Payments Of Dividends Minority Interest PaymentsOfDividendsMinorityInterest	37600000	USD
	us-gaap	Payments Of Dividends Preferred Stock And Preference Stock PaymentsOfDividendsPreferredStockAndPreferenceStock	18900000	USD
	us-gaap	Payments Of Dividends Preferred Stock And Preference Stock PaymentsOfDividendsPreferredStockAndPreferenceStock	17200000	USD
	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	28900000	USD
	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	3100000	USD
CY2012Q3	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	1000000	USD
CY2013Q3	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	0	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	166800000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	112500000	USD
	us-gaap	Payments To Acquire Restricted Investments PaymentsToAcquireRestrictedInvestments	8600000	USD
	us-gaap	Payments To Acquire Restricted Investments PaymentsToAcquireRestrictedInvestments	8100000	USD
	us-gaap	Proceeds From Contributions From Affiliates ProceedsFromContributionsFromAffiliates	9500000	USD
	us-gaap	Proceeds From Contributions From Affiliates ProceedsFromContributionsFromAffiliates	0	USD
	us-gaap	Proceeds From Issuance Of Senior Long Term Debt ProceedsFromIssuanceOfSeniorLongTermDebt	0	USD
	us-gaap	Proceeds From Issuance Of Senior Long Term Debt ProceedsFromIssuanceOfSeniorLongTermDebt	275000000	USD
	us-gaap	Proceeds From Long Term Lines Of Credit ProceedsFromLongTermLinesOfCredit	147000000	USD
	us-gaap	Proceeds From Long Term Lines Of Credit ProceedsFromLongTermLinesOfCredit	135000000	USD
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	0	USD
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	15200000	USD
	hls	Percentage Of Net Operating Revenues Other Income PercentageOfNetOperatingRevenuesOtherIncome	0.015
	hls	Percentage Of Net Operating Revenues Other Income PercentageOfNetOperatingRevenuesOtherIncome	0.017
	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	Yes
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	0	USD
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	10800000	USD
CY2013Q3	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	10800000	USD
	us-gaap	Proceeds From Sale Of Restricted Investments ProceedsFromSaleOfRestrictedInvestments	16900000	USD
	us-gaap	Proceeds From Sale Of Restricted Investments ProceedsFromSaleOfRestrictedInvestments	300000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	7500000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	400000	USD
	us-gaap	Profit Loss ProfitLoss	176600000	USD
CY2013Q3	us-gaap	Profit Loss ProfitLoss	72300000	USD
	us-gaap	Profit Loss ProfitLoss	317200000	USD
CY2012Q3	us-gaap	Profit Loss ProfitLoss	59900000	USD
CY2012Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	748000000	USD
CY2013Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	893500000	USD
CY2013Q3	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	8000000	USD
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	19800000	USD
CY2012Q3	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	7000000	USD
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	22400000	USD
CY2013Q3	us-gaap	Redeemable Noncontrolling Interest Equity Carrying Amount RedeemableNoncontrollingInterestEquityCarryingAmount	13900000	USD
CY2012Q4	us-gaap	Redeemable Noncontrolling Interest Equity Carrying Amount RedeemableNoncontrollingInterestEquityCarryingAmount	7200000	USD
	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	8600000	USD
	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	8900000	USD
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	101300000	USD
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	2500000	USD
	us-gaap	Repayments Of Long Term Lines Of Credit RepaymentsOfLongTermLinesOfCredit	245000000	USD
	us-gaap	Repayments Of Long Term Lines Of Credit RepaymentsOfLongTermLinesOfCredit	112000000	USD
CY2013Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-2150000000	USD
CY2012Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-2424700000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	19000000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	18100000	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	7500000	USD
CY2013Q3	us-gaap	Stockholders Equity StockholdersEquity	321100000	USD
CY2012Q4	us-gaap	Stockholders Equity StockholdersEquity	291000000	USD
CY2013Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	442000000	USD
CY2012Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	403500000	USD
CY2012Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	355400000	USD
CY2011Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	201000000	USD
	us-gaap	Stockholders Equity Other StockholdersEquityOther	1600000	USD
	us-gaap	Stockholders Equity Other StockholdersEquityOther	2000000	USD
CY2012Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	108100000	shares
CY2013Q3	us-gaap	Supplies Expense SuppliesExpense	25500000	USD
	us-gaap	Supplies Expense SuppliesExpense	78300000	USD
CY2012Q3	us-gaap	Supplies Expense SuppliesExpense	23800000	USD
	us-gaap	Supplies Expense SuppliesExpense	76200000	USD
CY2013Q3	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	342200000	USD
CY2012Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	342200000	USD
CY2012Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	5233521000000	shares
CY2013Q3	us-gaap	Treasury Stock Shares TreasuryStockShares	14643181000000	shares
CY2013Q3	us-gaap	Treasury Stock Value TreasuryStockValue	404200000	USD
CY2012Q4	us-gaap	Treasury Stock Value TreasuryStockValue	163300000	USD
	us-gaap	Undistributed Earnings Allocated To Participating Securities UndistributedEarningsAllocatedToParticipatingSecurities	-1600000	USD
CY2013Q3	us-gaap	Undistributed Earnings Allocated To Participating Securities UndistributedEarningsAllocatedToParticipatingSecurities	-600000	USD
	us-gaap	Undistributed Earnings Allocated To Participating Securities UndistributedEarningsAllocatedToParticipatingSecurities	-4100000	USD
CY2012Q3	us-gaap	Undistributed Earnings Allocated To Participating Securities UndistributedEarningsAllocatedToParticipatingSecurities	-600000	USD
CY2013Q3	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	3000000	USD
CY2012Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	78000000	USD
	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Settlements With Taxing Authorities UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities	-121700000	USD
CY2012Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0	USD
CY2013Q3	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	300000	USD
	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	46700000	USD
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	102400000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	108200000	shares
CY2013Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	100400000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	88700000	shares
CY2013Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	86200000	shares
CY2012Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	94700000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	94600000	shares
	hls	Cash Flow For Government Class Action And Related Settlements CashFlowForGovernmentClassActionAndRelatedSettlements	5900000	USD
	hls	Cash Flow For Government Class Action And Related Settlements CashFlowForGovernmentClassActionAndRelatedSettlements	2600000	USD
	hls	Government Class Action And Related Settlements Expense GovernmentClassActionAndRelatedSettlementsExpense	-3500000	USD
CY2012Q3	hls	Equity In Net Income Of Consolidated Affiliates EquityInNetIncomeOfConsolidatedAffiliates	0	USD
	hls	Equity In Net Income Of Consolidated Affiliates EquityInNetIncomeOfConsolidatedAffiliates	0	USD
CY2013Q3	hls	Equity In Net Income Of Consolidated Affiliates EquityInNetIncomeOfConsolidatedAffiliates	0	USD
	hls	Equity In Net Income Of Consolidated Affiliates EquityInNetIncomeOfConsolidatedAffiliates	0	USD
	hls	Equity Method Investment Summarized Financial Information Operating Expenses EquityMethodInvestmentSummarizedFinancialInformationOperatingExpenses	-32500000	USD
	hls	Equity Method Investment Summarized Financial Information Operating Expenses EquityMethodInvestmentSummarizedFinancialInformationOperatingExpenses	-37500000	USD
CY2012Q3	hls	Equity Method Investment Summarized Financial Information Operating Expenses EquityMethodInvestmentSummarizedFinancialInformationOperatingExpenses	-9600000	USD
CY2013Q3	hls	Equity Method Investment Summarized Financial Information Operating Expenses EquityMethodInvestmentSummarizedFinancialInformationOperatingExpenses	-10300000	USD
CY2013Q3	hls	Excess Tax Benefits From Share Based Compensation ExcessTaxBenefitsFromShareBasedCompensation	6200000	USD
CY2012Q3	hls	Government Class Action And Related Settlements Expense GovernmentClassActionAndRelatedSettlementsExpense	-3500000	USD
	hls	Government Class Action And Related Settlements Expense GovernmentClassActionAndRelatedSettlementsExpense	-23300000	USD
CY2013Q3	hls	Government Class Action And Related Settlements Expense GovernmentClassActionAndRelatedSettlementsExpense	-21300000	USD
	hls	Income Loss From Continuing Operations Attributable To Common Shareholders Basic IncomeLossFromContinuingOperationsAttributableToCommonShareholdersBasic	114900000	USD
CY2013Q3	hls	Income Loss From Continuing Operations Attributable To Common Shareholders Basic IncomeLossFromContinuingOperationsAttributableToCommonShareholdersBasic	52800000	USD
CY2012Q3	hls	Income Loss From Continuing Operations Attributable To Common Shareholders Basic IncomeLossFromContinuingOperationsAttributableToCommonShareholdersBasic	41300000	USD
	hls	Income Loss From Continuing Operations Attributable To Common Shareholders Basic IncomeLossFromContinuingOperationsAttributableToCommonShareholdersBasic	254600000	USD
CY2013Q3	hls	Income Loss From Continuing Operations Attributable To Common Shareholders Diluted IncomeLossFromContinuingOperationsAttributableToCommonShareholdersDiluted	59100000	USD
CY2012Q3	hls	Income Loss From Continuing Operations Attributable To Common Shareholders Diluted IncomeLossFromContinuingOperationsAttributableToCommonShareholdersDiluted	47600000	USD
	hls	Income Loss From Continuing Operations Attributable To Common Shareholders Diluted IncomeLossFromContinuingOperationsAttributableToCommonShareholdersDiluted	275900000	USD
	hls	Income Loss From Continuing Operations Attributable To Common Shareholders Diluted IncomeLossFromContinuingOperationsAttributableToCommonShareholdersDiluted	135400000	USD
	hls	Net Income Loss Availableto Common Stockholders NetIncomeLossAvailabletoCommonStockholders	253400000	USD
CY2012Q3	hls	Net Income Loss Availableto Common Stockholders NetIncomeLossAvailabletoCommonStockholders	40800000	USD
CY2013Q3	hls	Net Income Loss Availableto Common Stockholders NetIncomeLossAvailabletoCommonStockholders	51900000	USD
	hls	Net Income Loss Availableto Common Stockholders NetIncomeLossAvailabletoCommonStockholders	117500000	USD
	hls	Net Income Loss Including Portion Attributable To Nonredeemable Noncontrolling Interest Total NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterestTotal	173600000	USD
	hls	Net Income Loss Including Portion Attributable To Nonredeemable Noncontrolling Interest Total NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterestTotal	313100000	USD
	hls	Net Operating Revenues Less Provision For Doubtful Accounts NetOperatingRevenuesLessProvisionForDoubtfulAccounts	1589200000	USD
CY2012Q3	hls	Net Operating Revenues Less Provision For Doubtful Accounts NetOperatingRevenuesLessProvisionForDoubtfulAccounts	530000000	USD
CY2013Q3	hls	Net Operating Revenues Less Provision For Doubtful Accounts NetOperatingRevenuesLessProvisionForDoubtfulAccounts	556000000	USD
	hls	Net Operating Revenues Less Provision For Doubtful Accounts NetOperatingRevenuesLessProvisionForDoubtfulAccounts	1678700000	USD
CY2013Q3	hls	Number Of General Or Limited Partnerships Limited Liability Companies Or Joint Ventures NumberOfGeneralOrLimitedPartnershipsLimitedLiabilityCompaniesOrJointVentures	9	facilities
CY2013Q3	hls	Number Of Partially Owned Subsidiaries Nonconsolidated NumberOfPartiallyOwnedSubsidiariesNonconsolidated	12	facilities
	hls	Occupancy Cost OccupancyCost	36600000	USD
CY2012Q3	hls	Occupancy Cost OccupancyCost	11800000	USD
	hls	Occupancy Cost OccupancyCost	35800000	USD
CY2013Q3	hls	Occupancy Cost OccupancyCost	11700000	USD
	hls	Ownership Percentage Of Subsidiary Guarantors OwnershipPercentageOfSubsidiaryGuarantors	1.00
	hls	Percentage Of Net Operating Revenues Managed Care PercentageOfNetOperatingRevenuesManagedCare	0.185
	hls	Percentage Of Net Operating Revenues Managed Care PercentageOfNetOperatingRevenuesManagedCare	0.194
CY2013Q3	hls	Percentage Of Net Operating Revenues Managed Care PercentageOfNetOperatingRevenuesManagedCare	0.187
CY2012Q3	hls	Percentage Of Net Operating Revenues Managed Care PercentageOfNetOperatingRevenuesManagedCare	0.191
CY2012Q3	hls	Percentage Of Net Operating Revenues Medicaid PercentageOfNetOperatingRevenuesMedicaid	0.014
	hls	Percentage Of Net Operating Revenues Medicaid PercentageOfNetOperatingRevenuesMedicaid	0.013
	hls	Percentage Of Net Operating Revenues Medicaid PercentageOfNetOperatingRevenuesMedicaid	0.012
CY2013Q3	hls	Percentage Of Net Operating Revenues Medicaid PercentageOfNetOperatingRevenuesMedicaid	0.015
CY2012Q3	hls	Percentage Of Net Operating Revenues Medicare PercentageOfNetOperatingRevenuesMedicare	0.731
	hls	Percentage Of Net Operating Revenues Medicare PercentageOfNetOperatingRevenuesMedicare	0.745
CY2013Q3	hls	Percentage Of Net Operating Revenues Medicare PercentageOfNetOperatingRevenuesMedicare	0.741
	hls	Percentage Of Net Operating Revenues Medicare PercentageOfNetOperatingRevenuesMedicare	0.731
CY2012Q3	hls	Percentage Of Net Operating Revenues Other Income PercentageOfNetOperatingRevenuesOtherIncome	0.015
CY2013Q3	hls	Percentage Of Net Operating Revenues Other Income PercentageOfNetOperatingRevenuesOtherIncome	0.016
CY2013Q3	hls	Percentage Of Net Operating Revenues Other Third Party Payors PercentageOfNetOperatingRevenuesOtherThirdPartyPayors	0.017
CY2012Q3	hls	Percentage Of Net Operating Revenues Other Third Party Payors PercentageOfNetOperatingRevenuesOtherThirdPartyPayors	0.020
	hls	Percentage Of Net Operating Revenues Other Third Party Payors PercentageOfNetOperatingRevenuesOtherThirdPartyPayors	0.018
	hls	Percentage Of Net Operating Revenues Other Third Party Payors PercentageOfNetOperatingRevenuesOtherThirdPartyPayors	0.017
	hls	Percentage Of Net Operating Revenues Patients PercentageOfNetOperatingRevenuesPatients	0.011
CY2013Q3	hls	Percentage Of Net Operating Revenues Patients PercentageOfNetOperatingRevenuesPatients	0.011
CY2012Q3	hls	Percentage Of Net Operating Revenues Patients PercentageOfNetOperatingRevenuesPatients	0.014
	hls	Percentage Of Net Operating Revenues Patients PercentageOfNetOperatingRevenuesPatients	0.014
CY2013Q3	hls	Percentage Of Net Operating Revenues Total PercentageOfNetOperatingRevenuesTotal	1.000
	hls	Percentage Of Net Operating Revenues Total PercentageOfNetOperatingRevenuesTotal	1.000
	hls	Percentage Of Net Operating Revenues Total PercentageOfNetOperatingRevenuesTotal	1.000
CY2012Q3	hls	Percentage Of Net Operating Revenues Total PercentageOfNetOperatingRevenuesTotal	1.000
	hls	Percentage Of Net Operating Revenues Workers Compensation PercentageOfNetOperatingRevenuesWorkersCompensation	0.015
CY2013Q3	hls	Percentage Of Net Operating Revenues Workers Compensation PercentageOfNetOperatingRevenuesWorkersCompensation	0.013
	hls	Percentage Of Net Operating Revenues Workers Compensation PercentageOfNetOperatingRevenuesWorkersCompensation	0.013
CY2012Q3	hls	Percentage Of Net Operating Revenues Workers Compensation PercentageOfNetOperatingRevenuesWorkersCompensation	0.015
CY2008Q1	hls	Percentage Of Net Profit Due Company From Hospital Building Sale PercentageOfNetProfitDueCompanyFromHospitalBuildingSale	0.40
CY2012Q3	hls	Professional Fees Accounting Tax And Legal ProfessionalFeesAccountingTaxAndLegal	4100000	USD
	hls	Professional Fees Accounting Tax And Legal ProfessionalFeesAccountingTaxAndLegal	13200000	USD
CY2013Q3	hls	Professional Fees Accounting Tax And Legal ProfessionalFeesAccountingTaxAndLegal	4200000	USD
	hls	Professional Fees Accounting Tax And Legal ProfessionalFeesAccountingTaxAndLegal	7800000	USD
	hls	Repurchase Of Common Stock RepurchaseOfCommonStock	-234100000	USD
	hls	Repurchase Of Convertible Perpetual Preferred Stock RepurchaseOfConvertiblePerpetualPreferredStock	0	USD
CY2012Q3	hls	Repurchase Of Convertible Perpetual Preferred Stock RepurchaseOfConvertiblePerpetualPreferredStock	0	USD
	hls	Repurchase Of Convertible Perpetual Preferred Stock RepurchaseOfConvertiblePerpetualPreferredStock	800000	USD
CY2013Q3	hls	Repurchase Of Convertible Perpetual Preferred Stock RepurchaseOfConvertiblePerpetualPreferredStock	0	USD
CY2012	hls	Shareholders Equity Decreased Due To Reclassification Adjustment ShareholdersEquityDecreasedDueToReclassificationAdjustment	600000	USD
CY2012	hls	Temporary Equity Increased Due To Reclassification Adjustment TemporaryEquityIncreasedDueToReclassificationAdjustment	7200000	USD
CY2012	hls	Total Assets Increased Due To Reclassification Adjustment TotalAssetsIncreasedDueToReclassificationAdjustment	400000	USD
	dei	Entity Registrant Name EntityRegistrantName	HEALTHSOUTH CORP
	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2012Q2	dei	Entity Public Float EntityPublicFloat	2200000000	USD
CY2012	hls	Total Liabilities Decreased Due To Reclassification Adjustment TotalLiabilitiesDecreasedDueToReclassificationAdjustment	6200000	USD
	hls	Treasury Stock Reacquired TreasuryStockReacquired	11900000	USD
	hls	Treasury Stock Reacquired TreasuryStockReacquired	5800000	USD
	hls	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued Decreases Resulting From Settlements With Taxing Authorities UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccruedDecreasesResultingFromSettlementsWithTaxingAuthorities	0	USD
	hls	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccruedIncreasesResultingFromPriorPeriodTaxPositions	300000	USD
CY2012Q3	hls	Unrecognized Tax Benefits Reductions Resultingfrom Lapseof Applicable Statuteof Limitations And Settlements With Taxing Authorities UnrecognizedTaxBenefitsReductionsResultingfromLapseofApplicableStatuteofLimitationsAndSettlementsWithTaxingAuthorities	1000000	USD
	hls	Unrecognized Tax Benefits Reductions Resultingfrom Lapseof Applicable Statuteof Limitations And Settlements With Taxing Authorities UnrecognizedTaxBenefitsReductionsResultingfromLapseofApplicableStatuteofLimitationsAndSettlementsWithTaxingAuthorities	1000000	USD
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2013
	dei	Document Period End Date DocumentPeriodEndDate	2013-09-30
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0000785161
CY2013Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	87429848	shares
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer

Files In Submission

Name	View Source	Status
0000785161-13-000056-index-headers.html	Edgar Link	pending
0000785161-13-000056-index.html	Edgar Link	pending
0000785161-13-000056.txt	Edgar Link	pending
0000785161-13-000056-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
hls-20130930.xml	Edgar Link	completed
hls-20130930.xsd	Edgar Link	pending
hls-20130930_cal.xml	Edgar Link	unprocessable
hls-20130930_def.xml	Edgar Link	unprocessable
hls-20130930_lab.xml	Edgar Link	unprocessable
hls-20130930_pre.xml	Edgar Link	unprocessable
hls10q93013.htm	Edgar Link	pending
hls10q93013ex101.htm	Edgar Link	pending
hls10q93013ex311.htm	Edgar Link	pending
hls10q93013ex312.htm	Edgar Link	pending
hls10q93013ex321.htm	Edgar Link	pending
hls10q93013ex322.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$EHC
Encompass Health Corp Stock $ehc

2013 Q4 Form 10-Q Financial Statement

#000078516113000056 Filed on October 29, 2013

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$EHC Encompass Health Corp Stock $ehc

2013 Q4 Form 10-Q Financial Statement

#000078516113000056 Filed on October 29, 2013

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$EHC
Encompass Health Corp Stock $ehc